Multicentric Castleman's disease associated with inherited epidermolysis bullosa

被引:3
|
作者
Kawakami, Y
Nishibu, A
Kikuchi, S
Ohtsuka, M
Nakamura, K
Nozawa, Y
Abe, M
Iwatsuki, K
Kaneko, F
机构
[1] Fukushima Med Univ, Sch Med, Dept Dermatol, Fukushima 9601295, Japan
[2] Fukushima Med Univ, Sch Med, Dept Pathol 1, Fukushima 9601295, Japan
[3] Okayama Univ, Grad Sch Med & Dent, Dept Dermatol, Okayama 7008530, Japan
关键词
interleukin-6; hypergammaglobulinemia; dystrophic epidermolysis bullosa;
D O I
10.1111/j.1346-8138.2003.tb00459.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Multicentric Castleman's disease (MCD) is a rare disorder characterized by fever, polyclonal hypergammaglobulinemia, and generalized lymphadenopathy. It has three histological characteristics: a recognizable architecture, germinal center abnormalities, and plasmacytosis. Inherited epidermolysis bullosa (EB) is also a rare disorder caused by a genetic defect. We report a 43-year-old patient with dystrophic EB, non-Hallopeau-Siemens recessive type or dominant type, displaying clinicopathologic features of MCD. In addition, his serum interleukin-6, which is thought to be responsible for the clinical symptoms in MCD, was elevated.
引用
收藏
页码:689 / 693
页数:5
相关论文
共 50 条
  • [1] Successful treatment of multicentric Castleman's disease associated with dystrophic epidermolysis bullosa using anti-interleukin-6 receptor antibody
    Naruse, Satsuki
    Takashima, Shota
    Fujita, Yasuyuki
    Kataoka, Hiroshi
    Kawamura, Nobuaki
    Natsuga, Ken
    Ujiie, Hideyuki
    JOURNAL OF DERMATOLOGY, 2024, 51 (08) : e268 - e269
  • [2] Inherited epidermolysis bullosa
    Jo-David Fine
    Orphanet Journal of Rare Diseases, 5
  • [3] Kaposi's sarcoma-associated herpesvirus infection in the lung in multicentric Castleman's disease
    Hayashi, M
    Aoshiba, K
    Shimada, M
    Izawa, Y
    Yasui, S
    Nagai, A
    INTERNAL MEDICINE, 1999, 38 (03) : 279 - 282
  • [4] Dose selection of siltuximab for multicentric Castleman's disease
    Mayer, Christina L.
    Xie, Lanyi
    Bandekar, Rajesh
    Qi, Ming
    van de Velde, Helgi
    Reddy, Manjula
    Qin, Xiang
    Davis, Hugh M.
    Puchalski, Thomas A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (05) : 1037 - 1045
  • [5] Review of siltuximab in the treatment of multicentric Castleman's disease
    Sarosiek, Shayna
    Shah, Ruchit
    Munshi, Nikhil C.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (06) : 360 - 366
  • [6] Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report
    Pinto, Ana Luisa
    Gomes, Marilia
    Cipriano, Maria Augusta
    Ribeiro, Maria Leticia
    ACTA ONCOLOGICA, 2018, 57 (05) : 703 - 705
  • [7] Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide
    Lee, FC
    Merchant, SH
    AMERICAN JOURNAL OF HEMATOLOGY, 2003, 73 (01) : 48 - 53
  • [8] Orbital pseudotumor as an initial manifestation of multicentric Castleman's disease
    Inatani, M
    Kashii, S
    Nosaka, K
    Arima, N
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2005, 49 (06) : 505 - 508
  • [9] Orbital Pseudotumor as an Initial Manifestation of Multicentric Castleman's Disease
    Masaru Inatani
    Satoshi Kashii
    Kazumasa Nosaka
    Nobuyoshi Arima
    Japanese Journal of Ophthalmology, 2005, 49 : 505 - 508
  • [10] Mantle Cell Lymphoma Superimposed on Multicentric Castleman's Disease
    Yoshida, Tetsumi
    Sakai, Akira
    Imagawa, Jun
    Noda, Masaaki
    Takada, Shinichi
    Yoshino, Tadashi
    Kimura, Akiro
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2011, 51 (02) : 147 - 150